Agenus (AGEN) announced further details of its strategic realignment. Reductions are designed to reduce cash burn to $100M in FY25. This initiative follows the successful closing of a $22M mortgage secured by key real estate assets, providing the company with enhanced operational flexibility during this pivotal period. Agenus will concentrate its resources on its lead botensilimab/balstilimab program, which has demonstrated clinical activity in microsatellite stable colorectal cancer, non-small cell lung cancer, pancreatic cancer, sarcoma and other difficult-to-treat cancers. The company will implement significant cost-cutting measures, including staff reductions and operational adjustments, targeting a 60% reduction in annual expenditures and a cash burn of $100M for FY25. Agenus plans to transition its biologics CMC capabilities to a fee-for-service model. This initiative is intended to be supported by external funding.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AGEN:
- Agenus Secures $22M Mortgage to Advance Cancer Treatment
- Agenus secures $22M mortgage, announces strategic realignment
- Biotech Alert: Searches spiking for these stocks today
- Agenus Inc. Reports Progress in Immunotherapy Development
- Agenus reports Q3 EPS ($3.08) vs ($3.29) last year
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
